Abstract:Objective: To investigate the effect of calcium-independent phospholipase A(2) (iPLA(2)) inhibitor in reducing hepatocyte lipoapoptosis and improving insulin resistance. Methods: A total of 28 male Sprague-Dawley rats were randomly divided into the following three groups: 12 rats in group I (normal control group) were given normal diet for 18 weeks; 8 rats in group II (non-alcoholic fatty liver disease model group) were given high-fat diet for 18 weeks; 8 rats in group III (iPLA(2) inhibitor group) were given high-fat diet for 18 weeks and intraperitoneal injection of the iPLA(2) inhibitor bromoenol lactone 150 μg/kg once every other day since week 15 (14 times of injection in total). All the rats were sacrificed at the same time, and body weight and liver weight were measured. Blood lipids, serum enzymes, fasting blood glucose, fasting insulin, free fatty acid, and serum iPLA(2) concentration were measured in each group, and liver pathological changes were evaluated. The terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling was used to measure the level of hepatocyte apoptosis and the apoptotic index was calculated. Quantitative PCR was used to measure the mRNA expression of iPLA(2). The Student-Newman-Keuls test and the chi-square test were used for comparison of parameters between groups I, II, and III. P < 0.05 was considered statistically significant. Results: Compared with group I, group II had significant increases in triglyceride (0.75±0.05 mmol/L vs 1.20±0.13 mmol/L, P < 0.05), cholesterol (1.50±0.12 mmol/L vs 2.94±0.34 mmol/L, P < 0.05), low-density lipoprotein (0.65±0.06 mmol/L vs 1.30±0.16 mmol/L, P < 0.05), free fatty acid (0.58±0.09 mEq/L vs 0.80±0.20 mEq/L, P < 0.05), fasting blood glucose (4.85±0.22 mmol/L vs 6.94±0.65 mmol/L, P < 0.05), and fasting insulin (0.89±0.52 mmol/L vs 1.29±0.52 mmol/L, P < 0.05), and a significant reduction in the insulin sensitivity index (0.52±0.21 vs 0.27±0.11, P < 0.05); group II also had significant inflammation and fatty degeneration shown by liver pathology, and compared with group I, group II had significant increases in apoptotic cells and apoptotic index (0.58%±0.17% vs 39.69%±4.96%, P < 0.05). Compared with group I, group II had significant increases in serum iPLA(2) concentration (2.92±0.08 ng/ml vs 3.28±0.14 ng/ml, P < 0.05) and the mRNA expression of iPLA(2) in the liver (1.07±0.18 vs 7.68±0.49, P < 0.05). Compared with group II, group III had a lower level of hepatocyte apoptosis, a significant reduction in apoptotic index (39.69%±4.96% vs 24.80%±2.53%, P < 0.05), significant reductions in serum iPLA(2) concentration (3.28±0.14 ng/ml vs 2.64±0.24 ng/ml, P < 0.05) and the mRNA expression of iPLA(2) in the liver (7.68±0.49 vs 2.60±0.36, P < 0.05), significant reductions in fasting insulin (1.29±0.52 mmol/L vs 0.80±0.09 mmol/L, P < 0.05) and fasting blood glucose (6.94±0.65 mmol/L vs 5.18±0.35 mmol/L, P < 0.05), and a significant increase in insulin sensitivity index (0.27±0.11 vs 0.45±0.09, P < 0.05). Conclusion: There is a significant increase in the expression of iPLA(2) in rats with non-alcoholic fatty liver disease, and iPLA2 inhibitor can reduce hepatocyte lipoapoptosis and improve insulin resistance.

Metabolic Effects of Selective Deletion of Group VIA Phospholipase A<sub>2</sub> from Macrophages or Pancreatic Islet Beta-Cells

[Effect of Calcium-Independent Phospholipase A(2) Inhibitor in Reducing Hepatocyte Lipoapoptosis and Improving Insulin Resistance].

Effects of Stable Suppression of Group VIA Phospholipase A2 Expression on Phospholipid Content and Composition, Insulin Secretion, and Proliferation of INS-1 Insulinoma Cells*

Involvement in the Actions of Group VIA Calcium-Independent Phospholipase A2 in Β-Cells

Group VIA Phospholipase A2 (ipla2β) Modulates Bcl-x 5′-Splice Site Selection and Suppresses Anti-apoptotic Bcl-x(L) in Β-Cells

Genetic Modulation of Islet Β-Cell Ipla2β Expression Provides Evidence for Its Impact on Β-Cell Apoptosis and Autophagy

Deletion of the Von Hippel-Lindau Gene in Pancreatic Beta Cells Impairs Glucose Homeostasis in Mice.

Inhibition of Ca2+-Independent Phospholipase A2β (ipla2β) Ameliorates Islet Infiltration and Incidence of Diabetes in NOD Mice

Genetic Ablation of Calcium-independent Phospholipase A2γ Prevents Obesity and Insulin Resistance during High Fat Feeding by Mitochondrial Uncoupling and Increased Adipocyte Fatty Acid Oxidation

Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase.

Myeloid- and hepatocyte-specific deletion of group VIA calcium-independent phospholipase A2 leads to dichotomous opposing phenotypes during MCD diet-induced NASH

Evidence of Contribution of Ipla2β-Mediated Events During Islet Β-Cell Apoptosis Due to Proinflammatory Cytokines Suggests a Role for Ipla2β in T1D Development.

The Group Via Calcium-Independent Phospholipase A(2) Participates in Er Stress-Induced Ins-1 Insulinoma Cell Apoptosis by Promoting Ceramide Generation Via Hydrolysis of Sphingomyelins by Neutral Sphingomyelinase

Deletion of the RabGAP TBC1D1 Leads to Enhanced Insulin Secretion and Fatty Acid Oxidation in Islets From Male Mice

Alterations in Β-Cell Sphingolipid Profile Associated with ER Stress and Ipla2β: Another Contributor to Β-Cell Apoptosis in Type 1 Diabetes.

Role of Calcium-Independent Phospholipase A(2)β in Human Pancreatic Islet Β-Cell Apoptosis.

111-OR: Macrophage IPLA2ß-Derived Lipid (idl) Signaling Promote Type 1 Diabetes Development

Conditional ablation of Gsk-3β in islet beta cells results in expanded mass and resistance to fat feeding-induced diabetes in mice

Genetic Deletion of Calcium-independent Phospholipase A γ Protects Mice from Diabetic Nephropathy

Selective Reduction of Ca2+-Independent Phospholipase A2β (Ipla2β)-Derived Lipid Signaling from Macrophages Mitigates Type 1 Diabetes Development.

Group VIA Ca 2þ -Independent Phospholipase A2 (ipla2b) and Its Role in B-Cell Programmed Cell Death